Glucuronidase activator, pharmaceutical composition, edible composition, and oral composition
By using Lactobacillus brevis and other lactic acid bacteria of CECT 7480 to enhance glucuronidase activity, the side effects of hormone supplementation therapy were solved, and the effect of safe and efficient increase of estrogen levels and improving menopause symptoms was achieved.
Patent Information
- Application Number
- CN202380027134.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-17
- Filing Date
- 2023-03-14
- Publication Date
- 2024-11-22
AI Technical Summary
Existing hormone supplementation therapy is used to treat menopausal symptoms with side effects and it is difficult to safely and effectively improve women's estrogen levels, affecting the quality of life.
Lactobacillus brevis I-3141 strain of CECT 7480 was used as a glucuronidase activator, combining Lactoplantibacillus plantarum of CECT 7481 and Pediococcus acidilacticici of CECT 7483. ), enhance glucuronidase activity through oral administration and improve estrogen levels in the body.
It has achieved safe and efficient improvement of estrogen levels in the body, improved menopause symptoms, enhanced glucuronidase activity in the intestinal tract, improved estrogen metabolism, and reduced the side effects of hormone supplementation therapy.
Smart Images

Figure CN119013031A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a glucuronidase activator, a pharmaceutical composition, an edible composition and an oral composition. Background Art
[0002] As women age, the function of the ovaries declines, and thus the secretion of estrogen decreases significantly. In particular, the 10 years from 5 years before menopause to 5 years after menopause are called menopause, and during this period, various symptoms will appear in the body due to hormone imbalance. The symptoms produced during this menopause are called menopausal symptoms, and the state in which the symptoms are severe and cause obstacles to daily life is called menopausal disorder. In addition, in the case of early menopause due to reasons such as oophorectomy and hysterectomy, menopausal symptoms may also be felt.
[0003] Menopausal symptoms, no matter how severe they are, can cause mental distress to women. Under such circumstances, it is necessary to improve women's QOL (Quality of Life) by preventing or treating menopausal symptoms.
[0004] Menopausal symptoms are mainly classified into symptoms of central nervous system, skin, mucous membrane or hair, symptoms of sexual function, changes in body weight and metabolism, urogenital system symptoms, musculoskeletal system symptoms etc. (with reference to non-patent literature 1). The biggest reason that menopausal symptoms produce is the sharp reduction of the estrogen level in the body during menopause (with reference to non-patent literature 2). Therefore, as the Therapeutic Method of menopausal symptoms, the hormone replacement therapy (HRT) for supplementing the estrogen lacking has been mainly used. However, for hormone replacement therapy, as its side effect, there is the problem that the risk of occurrence of uterine bleeding, apoplexy, heart attack, breast cancer, uterine cancer, gastrointestinal disease, thrombosis, hepatopathy etc. increases.
[0005] Therefore, there is a strong demand for the development of a composition for preventing or treating menopausal symptoms that has no side effects and is highly safe and can prevent or treat menopausal symptoms.
[0006] Estrogen is produced in the ovary, adrenal gland, adipose tissue, other organs, etc., metabolized in the liver, and a part of it becomes glucuronic acid conjugate. The glucuronic acid conjugate is secreted into the intestine together with bile acid and excreted with feces. The glucuronic acid conjugate secreted into the intestine is debonded due to the activity of β-glucuronidase (GUS) possessed by intestinal bacteria, and the debonded estrogen is reabsorbed into the body (refer to non-patent literature 3).
[0007] It is known that a healthy state and sufficient estrogen levels can maintain the microbial diversity of the intestine. Under such conditions, beneficial bacteria are dominant, which can prevent the proliferation of pathogenic bacteria and maintain the stability of the intestinal flora. The intestinal flora is a complex community of microorganisms that form colonies in the gastrointestinal tract. On the other hand, for postmenopausal women, due to estrogen deficiency, the intestinal flora changes, the diversity of intestinal bacteria decreases, and the amount of intestinal bacteria decreases. In this regard, it is known that probiotics as nutritional supplements or medical supplements containing beneficial microorganisms work in synergy with intestinal microorganisms to maintain the health of the host (refer to non-patent literature 4).
[0008] Lactic acid bacteria, one of the intestinal bacteria, have long been used in beverages such as fermented foods, pharmaceuticals, probiotics, and the like. Lactic acid bacteria belonging to the genus Lactobacillus are also highly safe bacteria used in various applications.
[0009] Prior art literature
[0010] Non-patent literature
[0011] Non-patent literature 1: Patrizia Monteleone et al., Nature Reviews Endocrinology, 2018, 14(4), p.199-215
[0012] Non-patent literature 2: Nkechinyere Chidi-Ogbolu et al., Front Physiol, 2019, Vol. 9, Article 1834
[0013] Non-patent literature 3: Maryann Kwa et al., J Natl Cancer Inst, 2016, 8(8)
[0014] Non-patent literature 4: Xin Xu et al., Bone Research, 2017, 5, 17046 Summary of the invention
[0015] Problems to be solved by the invention
[0016] The present invention aims to solve the above-mentioned problems and achieve the following objectives: That is, the present invention aims to provide a glucuronidase activator, a pharmaceutical composition, a probiotic composition, and an edible composition having excellent glucuronidase activity and high safety.
[0017] Solution to the problem
[0018] Means for solving the above-mentioned problems are as follows.
[0019] <1> A glucuronidase activator comprising Levilactobacillus brevis I-3141 strain with the accession number CECT 7480 as an active ingredient.
[0020] <2> A method for enhancing the activity of glucuronidase, comprising administering Levilactobacillus brevis I-3141 strain, deposited as CECT 7480, to a subject to enhance the activity of glucuronidase.
[0021] <3> A pharmaceutical composition comprising the glucuronidase activator described in <1> above and a pharmaceutically acceptable carrier.
[0022] <4> An edible composition comprising the glucuronidase activator according to <1> above and an edible ingredient.
[0023] <5> An oral composition comprising Levilactobacillus brevis I-3141 strain with a deposit number of CECT 7480, Lactoplantibacillus plantarum with a deposit number of CECT 7481, and Pediococcus acidilactici with a deposit number of CECT 7483.
[0024] <6> A method for increasing estrogen levels, the method comprising: orally administering to a subject the glucuronidase activator described in <1> above, the pharmaceutical composition described in <3> above, the edible composition described in <4> above, or the oral composition described in <5> above.
[0025] <7> A method for improving estrogen metabolism, the method comprising: orally administering to a subject the glucuronidase activator described in <1> above, the pharmaceutical composition described in <3> above, the edible composition described in <4> above, or the oral composition described in <5> above.
[0026] <8> A method for improving menopausal symptoms, the method comprising: orally administering to a subject the glucuronidase activator described in <1> above, the pharmaceutical composition described in <3> above, the edible composition described in <4> above, or the oral composition described in <5> above.
[0027] Effects of the Invention
[0028] According to the present invention, the above-mentioned problems in the past can be solved, the above-mentioned objects can be achieved, and a glucuronidase activator, a pharmaceutical composition, a probiotic composition, and an edible composition having excellent glucuronidase activity and high safety can be provided. BRIEF DESCRIPTION OF THE DRAWINGS
[0029] Figure 1A The figure shows the electrophoretic pattern of pulsed field gel electrophoresis after genome digestion with Sfi-I restriction enzyme in order to determine the genotype of Levilactobacillus brevis I-3141 strain. "4" represents Levilactobacillus brevis I-3141 strain, "5" represents Lacticaseibacillus casei VSL#3, "6" represents Lacticaseibacillus casei DN114.001, and "M" represents a molecular weight marker.
[0030] Figure 1B It is a figure showing the electrophoresis pattern of pulsed field gel electrophoresis after genome digestion with Sma-I restriction enzyme in order to determine the genotype of Levilactobacillus brevis I-3141 strain. "4" represents Levilactobacillus brevis I-3141 strain, "5" represents Lacticaseibacillus casei VSL#3, "6" represents Lacticaseibacillus casei DN114.001, and "M" represents a molecular weight marker.
[0031] Figure 1C It is a figure which shows the electrophoresis pattern of pulsed field gel electrophoresis after genome digestion with Sfi-I restriction enzyme in order to determine the genotype of Lactoplantibacillus plantarum F-2096 strain. "1" represents Lactoplantibacillus plantarum F-2096 strain, "2" represents Lactoplan tibacillus plantarum299V, "3" represents Lacticaseibacillus casei VSL#3, and "M" represents molecular weight marker.
[0032] Figure 1DIt is a figure showing the electrophoresis pattern of pulsed field gel electrophoresis after genome digestion with Sma-I restriction enzyme to determine the genotype of Lactoplantibacillus plantarum F-2096 strain. "1" represents Lactoplantibacillus plantarum F-2096 strain, "2" represents Lactoplan tibacillus plantarum299V, "3" represents Lacticaseibacillus casei VSL#3, and "M" represents molecular weight marker.
[0033] Figure 1E It is a figure which shows the electrophoresis pattern of pulsed field gel electrophoresis after genome digestion with Not-I restriction enzyme in order to determine the genotype of Pediococcus acidilactici F-1033 strain. "1" represents Pediococcus acidilactici F-1033 strain, "4" represents Pediococcus acidilactici Rossell1001, and "M" represents molecular weight marker.
[0034] Figure 1F The figure shows the electrophoretic pattern of pulsed field gel electrophoresis after genome digestion with Sma-I restriction enzyme in order to determine the genotype of Pediococcus acidilactici F-1033 strain. "1" represents Pediococcus acidilactici F-1033 strain, "4" represents Pediococcus acidilactici Rossell1001, and "M" represents a molecular weight marker.
[0035] Figure 2 This is a graph showing the results of GUS activity when pNGP was used as a substrate in Test Example 2. "●" indicates the results of Levilactobacillus brevis I-3141 strain, "▲" indicates the results of Levilactobacillus brevis NBRC 107147, and "■" indicates the results of the negative control.
[0036] Figure 3 This is a graph showing the results of GUS activity when E1-3G was used as a substrate in Test Example 2. "●" indicates the results of Levilactobacillus brevis I-3141 strain, "▲" indicates the results of Levilactobacillus brevis NBRC 107147, and "■" indicates the results of the negative control.
[0037] Figure 4 This is a graph showing the results of GUS activity when E2-3G was used as a substrate in Test Example 2. "●" indicates the results of Levilactobacillus brevis I-3141 strain, "▲" indicates the results of Levilactobacillus brevis NBRC 107147, and "■" indicates the results of the negative control. DETAILED DESCRIPTION
[0038] (microorganism)
[0039] The microorganism of the present invention is the strain I-3141 of Levilactobacillus sbrevis with the deposit number of CECT 7480, which has glucuronidase activity. The microorganism can debind the glucuronic acid conjugate of estrogen through the glucuronidase activity.
[0040] Glucuronidase includes α-glucuronidase (EC 3.2.1.139) and β-glucuronidase (EC 3.2.1.31).
[0041] The α-glucuronidase is a hydrolase that uses α-D-glucuronide and water as substrates to generate alcohol and D-glucuronic acid.
[0042] The β-glucuronidase is a general term for enzymes that act on β-glycosides of D-glucuronic acid to hydrolyze the glucuronide bond. The β-glucuronidase has broad specificity for aglycones and also acts on β-D-glucuronides of alcohols, steroids, carboxylic acids, and the like.
[0043] Among them, the above-mentioned microorganism preferably has β-glucuronidase activity.
[0044] The method for confirming the glucuronidase activity of the above-mentioned microorganism is not particularly limited and can be appropriately selected from known methods. For example, a method of reacting a known glucuronidase substrate with the above-mentioned microorganism and confirming the presence or absence of a reaction product, or measuring the concentration of the reaction product can be mentioned.
[0045] The above-mentioned Levilactobacillus brevis I-3141 strain is described in Japanese Patent No. 5879349 (International Publication No. 2012 / 022773). The isolation method and taxonomic characteristics are shown below.
[0046] 1. Isolation of Microorganisms
[0047] The I-3141 strain was isolated from saliva of children aged 0 to 5 years old in undeveloped areas of tropical South America. The saliva was dissolved in PBS buffer (pH 7.4), pipetted, and inoculated on MRS (Man Rogosa Sharp, Sigma-Aldrich Chem, Spain) agar supplemented with 10 μg / ml vancomycin (made by SIGMA). The bacteria were cultured at 37°C and microaerobic conditions (5% CO2). After proliferation, the isolated strain was preserved by freeze drying in 0.1×PBS containing 15% by mass of skim milk powder.
[0048] 2. Taxonomic characteristics of strains
[0049] 2.1. Genetic identification of genus and species
[0050] A) Method
[0051] The above bacteria were cultured overnight in MRS medium (pH 6.4) at 37°C in a gas atmosphere containing 5% CO2. Further, the bacteria were recovered and washed, resuspended in the above lysis buffer (480 μL of EDTA 50mM pH 8.0; 120 μL of lysozyme 10 mg / mL), and further incubated at 37°C for 60 minutes. Genomic DNA was extracted using the Wizard genomic DNA purification kit (produced by Promega). The pre-treated bacteria were centrifuged at 14000g for 2 minutes, and after removing the supernatant, the Promega protocol was continued. In short, the bacteria were resuspended in a nuclear lysis solution, incubated at 80°C for 5 minutes, and then cooled to room temperature. The cell lysate was incubated in an RNase solution at 37°C for 60 minutes, and a protein precipitation solution was added to the protein, which was rotated at high speed to precipitate it. The sample was cooled and centrifuged at 15000g for 3 minutes. The supernatant containing the DNA was transferred to a clean 1.5 mL microcentrifuge tube and mixed with 600 μL of isopropanol by inversion. The DNA was recovered by centrifugation at 15,000 g for 2 minutes and the supernatant was carefully discarded. The DNA sample was washed with 600 μL of 70% by volume ethanol by gently inverting the tube several times. After centrifugation at 15,000 g for 2 minutes, the ethanol was removed by aspiration. Finally, the DNA pellet was resuspended in 100 μL of Rehydration solution by incubation at 65°C for 1 hour. The samples were stored at 2°C to 8°C.
[0052] 16S rRNA was amplified by PCR using universal primers Eub27f and Eub1492r for preparing a fragment of substantially the entire sequence of 16S (1000 nucleotides or more). Next, the DNA obtained as described above was cleaned using QIA (registered trademark) quick kit (manufactured by Qiagen).
[0053] Table 1 below shows the primers used for amplifying and sequencing the 16S gene.
[0054] Four consecutive sequencing reactions were performed using the primers and BigDye v.3.1 kit shown in Table 1 below using Genetic Analyzer r 3130 (Applied Biosystems). Data was recovered and chromatograms were prepared using DNA Sequence Analysis v.5.2 software (Applied Biosystems), and visual analysis was confirmed using Chromas (Technelysium Pty Ltd.) and BioEdit (Ibis Biosciences).
[0055] The genus identification was performed using the Ribosomal Database Project tool (Wang Q et al., "NaiveBayesian Classifier for Rapid Assignment of rRNA Sequences into the New Bacteial Taxonomy", Appl Environ Microbiol, 2007, vol. 73, p. 5261-5267). The species identification was performed by comparing the sequences obtained from the 16S sequences of known organisms based on the RefSeq database (http: / / www.ncbi.nlm.nih.gov / RefSeq / ) based on the BLASTN method and the Ribosomal Database Project (http: / / rdp.cme.msu.edu / , JR Col et al., "The Ribosomal Database Project (RDP-II): introducing myRDP space and quality controlled public data", Nucl. Acids Res., 2007, vol. 35, p. 169-172).
[0056] [Table 1]
[0057]
[0058] B) Results
[0059] The I-3141 strain was identified as belonging to the species Levilactobacillus brevis using the RDP (Ribosomal Database Project) tool.
[0060] 2.2. Determination of strain genotype
[0061] A) Method
[0062] The characteristics were evaluated by genomic digestion and pulsed field gel electrophoresis. The I-3141 strain was subjected to a previously described experimental protocol (Rodas AM et al., "Polyphasic study of wine Lactobacillus strains: taxonomic implications", Int J Syst Evol Microbiol, 2005, vol. 55, p. 197-207). The commercially available strain Lactobacillus casei ( Lacticaseibacillus casei )VSL#3 and Lacticaseibacillus casei DN114.001 was included in the test as a control strain. All strains were propagated on MRS agar plates and incubated at 37°C, 5% CO2 for 18 hours. The cells were recovered and washed three times in 8 mL of PET (10 mM Tris pH 7.6, 1 M NaCl), followed by centrifugation at 6000 rpm for 10 minutes. The particles were resuspended in 700 μL of lysis buffer (6 mM Tris, 1 M NaCl, 0.1 M EDTA, 0.5% SLS, 0.2% deoxycholic acid; 1 mg / mL lysozyme; 40 U / mL mutanolysin; 20 g / mL RNase). An equal volume of 1.6% low melting point agarose (FMC BioProducts, Rockland, ME, USA) was added to the resuspended cells and allowed to solidify at 4°C for 1 hour. The insert was transferred to 2 mL of lysis buffer II (0.5 M EDTA pH 9.2, 1% N-lauroylsarcosine and 1 mg / mL pronase) and incubated at 50°C for 48 hours. Then, the insert was washed with TE buffer (10 mM Tris, 1 mM EDTA pH 8.0) at room temperature. The whole DNA was digested with Sfi-I restriction enzyme or Sma-I restriction enzyme (the above, manufactured by Roche Diagnostics).
[0063] Pulsed field electrophoresis was performed using a CHEF DRIII apparatus (BioRad Laboratories). The insert was loaded onto a 1% agarose gel (SeaKem ME agarose, FMC BioProducts, ME, USA). Table 2 below shows the electrophoresis status for Sfi-I or Sma-I restricted genomic DNA from strain I-3141. DNA molecular weight markers were Lambdaladder PFG Marker and Low Range PFG Marker (both manufactured by New England Biolabs). After electrophoresis, the gel was stained with ethidium bromide and UV using GelDoc Sy stem (manufactured by BioRad).
[0064] It should be noted that Lacticaseibacillus casei VSL#3 used as a control strain was isolated from VSL#3 (registered trademark) (manufactured by Alfasigma USA, Inc.) on an MRS agar plate. In addition, Lacticaseibacillus casei DN114.001 was isolated from Actimel (registered trademark) (manufactured by Danone) on an agar plate. All cells were cultured at 37°C and 5% CO2.
[0065] [Table 2]
[0066]
[0067] B) Results
[0068] like Figure 1A and Figure 1B As shown, the cleavage pattern obtained by digestion of the I-3141 strain with Sfi-I or Sma-I was similar to that of the closely related commercially available Lacticaseibacillus casei The strains are different.
[0069] Based on the above results, it can be considered that strain I-3141 belongs to Levilactobacillus brevis Therefore, the I-3141 strain was used as Levilactobacillus brevis I-3141 strain (hereinafter, sometimes simply referred to as "I-3141 strain").
[0070] It should be noted that the I-3141 strain was applied for deposit by the depositor AB-BIOTICS SA (located at Av. Torre Blanca 57 ESADE Creapolis Building Sant Cugat del Valles 08172 Spain) at the Spanish Type Culture Collection (COLECCION ESPANOLA DE CULTIVOS TIPO (CECT)) (located at Edificio 3 CUE. Parc Cientific Universitat de Valenci a Catedratico Agustin Escardino, 946980 Paterna (Valencia) Spain), and was internationally deposited on January 29, 2013 with the deposit number: CECT 7480.
[0071] It should be noted that due to previous reports Lactobacillus The genus Bacteria is phylogenetically diverse, and the physiological and biochemical characteristics vary greatly among species. Therefore, the genus classification was carried out at the genome level in 2020. (See Zheng J et al., Int J Syst Evol Microbiol, 2020, Ap r; 70(4), p. 2782-2858).
[0072] I-3141 strain belongs to Levilactobacillus brevis Corresponding to the 2020 genus classification, the previous classification of Lactobacillus brevis ( Lactobacillus brevis ).
[0073] As seen in other bacteria, the properties of the I-3141 strain may be changed. The microorganism of the present invention only needs to have the above-mentioned glucuronidase activity, and also includes strains in which the properties of the I-3141 strain are changed.
[0074] Examples of strains in which the properties of the above-mentioned I-3141 strain have been changed include mutant strains derived from the I-3141 strain (for example, natural mutant strains, artificial mutant strains that can be obtained through mutation treatments such as ultraviolet rays, X-rays, radiation, chemicals, etc.), genetically modified organisms (for example, transformants), etc.
[0075] Examples of methods for culturing the microorganisms include a method in which the microorganisms are inoculated into a nutrient medium (hereinafter, sometimes simply referred to as “medium”) and cultured at a temperature at which the microorganisms can grow.
[0076] The nutrient medium is not particularly limited and may be appropriately selected depending on the intended purpose. For example, a known medium conventionally used for culturing lactic acid bacteria may be used.
[0077] The nutrient source added to the nutrient medium is not particularly limited and can be appropriately selected depending on the intended purpose.
[0078] As the carbon source, for example, organic carbon compounds such as D-ribose, D-galactose, D-glucose, D-fructose, D-mannose, D-mannitol, N-acetylglucosamine, amygdalin, arbutin, esculin, salicin, D-cellobiose, D-maltose, sucrose, D-trehalose, gentiobiose, molasses, taffy, and oils can be used.
[0079] As the nitrogen source, for example, organic or inorganic nitrogen compounds such as meat extract, casein, peptone, yeast extract, dry yeast, germ, soybean meal, urea, amino acids, peptides, corn steep liquor, and ammonium salts can be used.
[0080] Inorganic salts such as sodium salts, potassium salts, calcium salts, magnesium salts, phosphates, iron salts, copper salts, zinc salts, and cobalt salts may also be used.
[0081] In addition, organic acids such as citric acid, vitamins such as biotin and vitamin B1, cystine, surfactants, methyl oleate, lard and other growth-promoting substances can be used.
[0082] The materials of these nutrient media can be any materials that can be used for the I-3141 strain, and any known culture materials can be used.
[0083] The pH of the culture medium is not particularly limited as long as it is within a range that does not substantially inhibit the growth of the microorganisms, but is preferably 3.0 to 8.0.
[0084] Examples of the prepared nutrient medium include MRS medium, GAM medium, and Rogosa medium.
[0085] As the culture condition of above-mentioned microorganism, there is no particular restriction, can carry out according to the general culture condition that the Lactobacill us genus microorganism is carried out, under the situation of liquid culture method, preferably carry out static culture.As the scale of cultivation, there is no particular restriction, can cultivate with test tube, flask, fermentation tank etc.
[0086] The culture temperature of the microorganisms is not particularly limited as long as it is a range that does not substantially inhibit the growth of the microorganisms, but is preferably 15°C to 45°C, and more preferably 30°C to 40°C.
[0087] The culture period is not particularly limited and can be appropriately selected depending on the intended purpose.
[0088] Known examples of the glucuronic acid conjugates of the above-mentioned estrogens existing in the body include estrone 3-(β-D-glucuronide) (E1-3G) represented by the following structural formula (1), estradiol 3-(β-D-glucuronide) (E2-3G) represented by the following structural formula (2), estradiol 17-(β-D-glucuronide) (E2-17G) represented by the following structural formula (3), estriol 3-(β-D-glucuronide) (E3-3G) represented by the following structural formula (4), estriol 16-(β-D-glucuronide) (E3-16G) represented by the following structural formula (5), and estriol 17-(β-D-glucuronide) (E3-17G) represented by the following structural formula (6).
[0089] [Chemical formula 1]
[0090]
[0091] [Chemical formula 2]
[0092]
[0093] [Chemical formula 3]
[0094]
[0095] [Chemical formula 4]
[0096]
[0097] [Chemical formula 5]
[0098]
[0099] [Chemical formula 6]
[0100]
[0101] There are three types of estrogen: estrone (E1), estradiol (E2), and estriol (E3). The main estrogen produced before menopause is estradiol (E2).
[0102] The above-mentioned E1-3G becomes estrone (E1) after being unbound, the above-mentioned E2-3G or the above-mentioned E2-17G becomes estradiol (E2) after being unbound, and the above-mentioned E3-3G, the above-mentioned E3-16G or the above-mentioned E3-17G becomes estriol (E3) after being unbound (refer to Samantha M. Ervin et al., J Biol Chem, 2019 Dec 6, 294 (49), p. 18586-18599).
[0103] The microorganism can decouple any one of E1-3G, E2-3G, E2-17G, E3-3G, E3-16G, and E-17G, and preferably decouples the glucuronic acid conjugate E2-3G.
[0104] -use-
[0105] The above-mentioned microorganism has glucuronidase activity and is highly safe. Therefore, the above-mentioned microorganism can be preferably used for the increase of the estrogen level in the body, the improvement of the estrogen metabolism in the body, the improvement of the menopausal symptoms or the enhancement of the glucuronidase activity in the intestinal tract. In addition, the above-mentioned microorganism can also be preferably used for the glucuronidase activator, pharmaceutical composition, probiotic composition, edible composition, oral composition and the composition containing microorganism described later. In addition, it can be preferably used as the enhancement method of the glucuronidase activity of the above-mentioned microorganism to the object administration and enhancing the glucuronidase activity. These are all included in the scope of the present invention.
[0106] In the present specification, "an increase in estrogen levels" means that the estrogen concentration in the body increases after administration of the glucuronidase activator or in the administration group, compared to before administration of the glucuronidase activator or in the non-administration group.
[0107] The method for measuring the estrogen level in the body is not particularly limited and can be appropriately selected from known methods. Examples thereof include methods for measuring the estrogen concentration in the blood by enzyme immunoassay, chemiluminescent immunoassay, chemiluminescent enzyme immunoassay, liquid chromatography, gas chromatography, liquid chromatography-mass spectrometry, and the like.
[0108] In addition, in this specification, "improvement of estrogen metabolism" refers to the above-mentioned Levilactobacillus brevis The glucuronidase activity of the I-3141 strain brings the estrogen level or estrogen metabolism in the body close to a healthy state, or restores it to a healthy state.
[0109] In addition, in this specification, "healthy state" means a state in which estrogen metabolism is equivalent to that before menopause, or a state in which menopausal symptoms are not felt.
[0110] In the method of using the above-mentioned microorganism as a glucuronidase activator, the above-mentioned microorganism may be used together with a microorganism selected from the group consisting of Lactobacillus plantarum ( Lactoplantibacillus plantarum) and at least any lactic acid bacteria belonging to Pediococcus acidilactici are used together. From the viewpoint of enhancing the glucuronidase activity, it is preferred to use the above-mentioned microorganism (strain I-3141), the lactic acid bacteria belonging to Lactoplantibacillus plantarum Lactobacillus, and Pediococcus acidilactici Of the three lactic acid bacteria, it is more preferred to use the above-mentioned microorganism (strain I-3141), the lactic acid bacteria with a deposit number of CECT 7481 Lactoplantibacillus plantarum , and the accession number is CECT 7483 Pedioco ccus acidilactici These three types of lactic acid bacteria.
[0111] (Glucuronidase Activator)
[0112] The glucuronidase activator of the present invention contains the Levilactobacillus brevis The I-3141 strain may be used as an active ingredient and may further contain other ingredients as necessary.
[0113] Normally, the glucuronide conjugates of estrogen secreted into the intestine are deconjugated by the β-glucuronidase activity of intestinal bacteria, converted into estrogen, and reabsorbed by the intestine. However, with menopause and aging, the level of estrogen in the body decreases.
[0114] In this regard, the I-3141 strain contained in the above-mentioned glucuronidase activator has glucuronidase activity and can deconjugate glucuronic acid conjugates of estrogen, and is highly safe. Therefore, for example, by taking the above-mentioned glucuronidase activator, the deconjugate of glucuronic acid conjugates of estrogen secreted into the intestine can be promoted, which is advantageous from the viewpoint of increasing the estrogen level in the body.
[0115] <I-3141 strain>
[0116] The above-mentioned glucuronidase activator contains the deposit number CECT 7480 Levilactobacillus brevis The I-3141 strain is as described in the above-mentioned section (microorganism).
[0117] The state of the I-3141 strain contained in the glucuronidase activator is not particularly limited and may be appropriately selected depending on the intended purpose, but is preferably a living cell or a disrupted cell of the I-3141 strain.
[0118] The live cells may be wet cells or dry cells, and specific examples include a culture of the I-3141 strain, a concentrate of the culture, a dry product of the culture, a dilution of the culture, and the like.
[0119] The method for drying the culture is not particularly limited unless the effects of the present invention are impaired, and the method may be appropriately selected from known methods. Examples thereof include spray drying, freeze drying, vacuum drying, and drum drying.
[0120] The disrupted bacterial cells refer to a state in which there are no unbroken bacterial cells under microscopic observation.
[0121] The method for obtaining the disrupted bacterial cells is not particularly limited unless the effects of the present invention are impaired, and can be appropriately selected from known methods, such as bead disruption, pressure disruption, ultrasonic disruption, and rotary blade disruption.
[0122] The content of the I-3141 strain in the glucuronidase activator is not particularly limited as long as the glucuronidase activity can be exerted, and can be appropriately selected according to the purpose. It should be noted that the glucuronidase activator may be the I-3141 strain itself.
[0123] <Other ingredients>
[0124] As the above-mentioned other components in the above-mentioned glucuronidase activator, there is no particular limitation as long as the effect of the present invention is not impaired, and components used in known pharmaceuticals, foods, cosmetics, etc. can be appropriately selected according to the dosage form, etc., and examples thereof include: excipients, binders, disintegrants, lubricants, flavoring agents, odor correctors, moisture-proofing agents, preservatives, reinforcing agents, thickeners, emulsifiers, antioxidants, sweeteners, acidulants, flavoring agents, colorants, fragrances, oily components, ultraviolet absorbers, surfactants, thickeners, alcohols, powdered components, toners, aqueous components, water, oils and fats, lactic acid bacteria other than I-3141 strains, etc. These can be used alone or in combination of two or more.
[0125] The content of the other components in the glucuronidase activator is not particularly limited unless the effects of the present invention are impaired, and may be appropriately selected depending on the intended purpose.
[0126] <<Lactic acid bacteria other than I-3141 strain>>
[0127] As lactic acid bacteria other than the I-3141 strain, there is no particular limitation as long as the effects of the present invention are not impaired, and they can be appropriately selected from known lactic acid bacteria. From the viewpoint of increasing the estrogen level in the body, improving the estrogen metabolism in the body, or improving the symptoms of menopause, preferably, they belong to Lactobacillus plantarum ( Lactoplantibacillus plantarum ) Lactic acid bacteria, belonging to Pediococcus acidilactici ( Pediococcus acid ilactici ) Lactic acid bacteria. These may be used alone or in combination of two or more.
[0128] belong- Lactoplantibacillus plantarum Lactic acid bacteria -
[0129] As the above Lactoplantibacillus plantarum The lactic acid bacteria are not particularly limited as long as the effects of the present invention are not impaired, and are preferably Lactobacillus plantarum (CECT 7481). Lac toplantibacillus plantarum )F-2096 strain.
[0130] Above Lactoplantibacillus plantarum The F-2096 strain is described in International Publication No. 2012 / 022773. The isolation method and taxonomic characteristics are shown below.
[0131] The F-2096 strain, like the I-3141 strain, was isolated from the saliva of children aged 0 to 5 years old in an undeveloped area of tropical South America. It was isolated by the method described in "1. Isolation of microorganisms" of the I-3141 strain, and was identified as belonging to the species of the fungus by the method described in "2.1. Genetic identification of genus and species" of "2. Taxonomic characteristics of strains" of the I-3141 strain, Ped iococcus acidilactici kind.
[0132] In addition, the genotype of the F-2096 strain was determined by the following method.
[0133] In the "A) method of "2.2. Determination of the genotype of the strain" of the I-3141 strain, the commercially available strain Lacticaseibacillus casei VSL#3 and Lacticaseibacillus casei DN114.001 was included in the test as a control strain and was changed to Lactobacillus plantarum ( Lact oplantibacillus plantarum )299V and Lactobacillus casei ( Lacticaseibacillus casei) VSL#3 was included in the test as a control strain. The genotype of the F-2096 strain was determined by the same method as the "A) method" of "2.2. Determination of the genotype of the strain" for the I-3141 strain.
[0134] It should be noted that the control strain used Lactoplantibacillus plantarum As 299V, a strain isolated from Ideal Bowel Support (registered trademark) (manufactured by Jarrow Formula Co., Ltd.) and cultured on an MRS agar plate at 37°C and 5% CO 2 was used.
[0135] As a result, if Figure 1C and Figure 1D As shown, the cleavage pattern obtained by digestion of the F-2096 strain with Sfi-I or Sma-I was similar to that of the closely related commercially available Lactoplantibacillus plantarum 299V and Lacticaseibacillus casei VSL#3 is different.
[0136] Based on the above results, it can be considered that the F-2096 strain belongs to Lactoplantibacillus plantarum Therefore, the F-2096 strain was used as Lactoplantibacillus plantarum F-2096 strain (hereinafter, sometimes simply referred to as "F-2096 strain").
[0137] It should be noted that the F-2096 strain was applied for deposit by the depositor AB-BIOTICS SA (located at Av. Tor re Blanca 57 ESADE Creapolis Building Sant Cugat del Valles 08172 Spain) at the Spanish Type Culture Collection (COLECCION ESPANOLA DE CULTIVOSTIPO (CECT)) (located at Edificio 3 CUE. Parc Cientific Universitat de Valencia Catedratico Agustin Escardino, 946980 Paterna (Valencia) Spain), and was internationally deposited on January 29, 2013 with the deposit number: CECT 7481.
[0138] It should be noted that due to previous reports LactoplantibacillusThe genus Bacteria is phylogenetically diverse, and the physiological and biochemical characteristics vary greatly among species. Therefore, the genus classification was carried out at the genome level in 2020. (See Zheng J et al., Int J Syst Evol Microbiol, 2020, Apr; 70(4), p. 2782-2858).
[0139] F-2096 strain belongs to Lactoplantibacillus plantarum Corresponding to the genus classification in 2020, the previous classification of Lactobacillus plantarum ( Lactobacillus plantarum ).
[0140] As seen in other bacteria, the properties of the F-2096 strain sometimes change. For the above-mentioned glucuronidase activator, as long as the relevant characteristics and advantages described in this specification are maintained or enhanced, and as long as the effects of the present invention are not impaired, strains in which the properties of the F-2096 strain have changed are also included.
[0141] Examples of strains in which the properties of the above-mentioned F-2096 strain have been changed include mutant strains derived from the F-2096 strain (for example, natural mutant strains, artificial mutant strains that can be obtained through mutation treatments such as ultraviolet rays, X-rays, radiation, chemicals, etc.), genetically modified organisms (for example, transformants), etc.
[0142] As a cultivation of the above Lactoplantibacillus plantarum The method for culturing the lactic acid bacteria of the present invention can be carried out by the same method as the method for culturing the microorganism of the present invention, and the same conditions as the medium etc. can be used.
[0143] As the above-mentioned glucuronidase activator contained in the above-mentioned Lactoplantibacillus pl antarum The state of the lactic acid bacteria is not particularly limited and can be appropriately selected according to the purpose, and is preferably the above-mentioned Lactobacillus plants Live cells of lactic acid bacteria or fragments of the cells.
[0144] The above-mentioned living cells may be wet cells or dry cells. Specific examples thereof include: Lactobacillus plants The invention also includes a culture of lactic acid bacteria, a concentrate of the culture, a dried product of the culture, a dilution of the culture, and the like.
[0145] -belong Pediococcus lactic acid Lactic acid bacteria -
[0146] As the above Pediococcus lactic acid The lactic acid bacteria are not particularly limited as long as the effects of the present invention are not impaired, and are preferably Pediococcus acidilactici (CECT 7483). Pediococci lactic acid )F-1033 strain.
[0147] Above Pediococcus lactic acid The F-1033 strain is described in Japanese Patent No. 5777640 (International Publication No. 2011 / 092261). The isolation method and taxonomic characteristics are shown below.
[0148] 1. separation of microorganisms
[0149] A) Method
[0150] The F-1033 strain was isolated from excrement and saliva of children aged 0 to 5 years (Daniel, C., et al., "Selecting Lactic Acid Bacteria for Their Safety and Functionality by Use of a Mouse Colitis Model", Appl. Environ. Microbiol., 2006, vol. 72, p. 5799-5805.). The new excrement and saliva were dissolved in PBS buffer (pH 7.4), pipetted, and inoculated on an MRS agar plate containing a composition of various antibiotics. The bacteria were cultured at 37°C and microaerobic conditions (5% CO2). The incubation time depends on the proliferation rate and usually takes 24 hours to 3 days. For initial identification, Gram staining was performed. After proliferation, the isolated strain was stored by freeze-drying in 0.1× PBS containing 15% by mass of skimmed milk powder.
[0151] B) Results
[0152] The isolated bacteria were grown on MRS agar supplemented with 10 μg / ml vancomycin (manufactured by SIGMA). Microscopic examination showed that the F-1033 strain was Gram-positive with a coccal morphology.
[0153] 2. The characteristics of the classification of bacteria
[0154] 2.1
[0155] A) Method
[0156] The bacteria isolated by the method described in "2.1. Genetic identification of genus and species" "A) Method" of "2. Taxonomic characteristics of strains" of I-3141 strain were the above-mentioned bacteria confirmed to be Gram-positive. DNA was extracted by the same method as "2.1. Genetic identification of genus and species" "A) Method" of "2. Taxonomic characteristics of strains" of I-3141 strain, and the obtained DNA pellets were incubated at 65°C for 1 hour, and then resuspended in 100 μL of rehydration solution to obtain a sample. The obtained sample was stored at 2°C to 8°C.
[0157] The 16S gene was amplified by PCR using universal primers 27f and 1492r (Weisburg, WG, et al., "16S ribosomal DNA amplification for physiology study", J. Bacteriol., 1991, vol. 173, p. 697-703.) for preparing a substantially complete length 16S rRNA fragment (1,465 bp). Then, the DNA obtained as described above was cleaned using a QIA (registered trademark) quick kit (manufactured by Qiagen, GmbH, Hilden, Germany).
[0158] Table 3 below shows the primers used for amplifying and sequencing the 16S gene.
[0159] Four consecutive sequencing reactions were performed using the primers and BigDye v.3.1 kit shown in Table 3 below using Genetic Analyzer r 3130 (Applied Biosystems). Data was recovered and chromatograms were prepared using DNA Sequence Analysis v.5.2 software (Applied Biosystems), and visual analysis was confirmed using Chromas (Technelysium Pty Ltd.) and BioEdit (Ibis Biosciences).
[0160] The obtained sequence was compared with the 16S sequence of known organisms to identify the genus and species. The 16S sequence of the known organism was obtained from both the BLASTN search (Altschul, SF, et al., "Basic local alignment search tool", J. Mol. Biol., 1990, vol. 215, p. 403-410.) and the RefSeq database (http: / / www.ncbi.nlm.nih.gov / RefSeq / ) of the above-mentioned Ribosomal Database Project tool.
[0161] [Table 3]
[0162]
[0163] B) Results
[0164] The strain F-1033 was identified as Pediococcus lactic acid kind.
[0165] 2.2
[0166] A) Method
[0167] The genotype of the F-1033 strain was determined by the same method as the "A) method" in "2.2. Determination of the genotype of the strain" for the I-3141 strain, except that the commercially available strains Lacticaseibacillus casei VSL#3 and Lacticaseibacillus casei DN114.001 were included in the test as control strains and were changed to the commercially available strain Pediococcus acidila ctici Rossell 1001 (manufactured by Rossell (registered trademark) Institute, Canada), and the restriction enzyme used for total DNA digestion was changed from Sfi-I restriction enzyme or Sma-I restriction enzyme to Not-I or Sma-I restriction enzyme (these are manufactured by Roche Diagnostics).
[0168] B) Results
[0169] like Figure 1F As shown, the F-1033 strain showed similar Pediococcus and IdiopathicSame cut pattern as Rossell 1001. However, Figure 1E As shown, the F-1033 strain showed similarity to that in the digestion with Not-I. Pediococcus lactic acid Rossell 1001 has a distinctly different cut-off pattern.
[0170] Based on the above results, it can be considered that the F-1033 strain belongs to Pediococcus lactic acid Therefore, the F-1033 strain was used as Pediococcus lactic acid F-1033 strain (hereinafter, sometimes simply referred to as "F-1033 strain").
[0171] It should be noted that the F-1033 strain was applied for deposit by the depositor AB-BIOTICS SA (located at Av. Tor re Blanca 57 ESADE Creapolis Building Sant Cugat del Valles 08172 Spain) at the Spanish Type Culture Collection (COLECCION ESPANOLA DE CULTIVOSTIPO (CECT)) (located at Edificio 3 CUE. Parc Cientific Universitat de Valencia Catedratico Agustin Escardino, 946980 Paterna (Valencia) Spain), and was internationally deposited on June 28, 2012 with the deposit number: CECT 7483.
[0172] As seen in other bacteria, the properties of the F-1033 strain sometimes change. For the above-mentioned glucuronidase activator, as long as the relevant characteristics and advantages described in this specification are maintained or enhanced, and as long as the effects of the present invention are not impaired, strains in which the properties of the F-1033 strain have changed are also included.
[0173] Examples of strains in which the properties of the above-mentioned F-1033 strain have been changed include mutant strains derived from the F-1033 strain (e.g., natural mutant strains, artificial mutant strains that can be obtained through mutation treatments such as ultraviolet rays, X-rays, radiation, chemicals, etc.), genetically modified organisms (e.g., transformants), etc.
[0174] As a cultivation of the above Pediococcus lactic acid The method for culturing the lactic acid bacteria of the present invention can be carried out by the same method as the method for culturing the microorganism of the present invention, and the same conditions as the medium etc. can be used.
[0175] As the above-mentioned glucuronidase activator contained in the above-mentioned Pediococcus lactic acid The state of the lactic acid bacteria is not particularly limited and can be appropriately selected according to the purpose, and is preferably the above-mentioned Pediococcus lactic acid Live cells of lactic acid bacteria or fragments of the cells.
[0176] The above-mentioned living cells may be wet cells or dry cells. Specific examples thereof include: Pediococcus lactic acid The invention also includes a culture of lactic acid bacteria, a concentrate of the culture, a dried product of the culture, a dilution of the culture, and the like.
[0177] From the viewpoint of enhancing the activity of glucuronidase, the glucuronidase activator preferably includes strain I-3141, Lactobacillus plants Lactobacillus, and Pediococcus lactic acid The three lactic acid bacteria are preferably lactic acid bacteria including strain I-3141 and strain CECT 7481. Lactobacillus plants , and the accession number is CECT 7483 Pediococcus lactic acid These three types of lactic acid bacteria.
[0178] As the above-mentioned glucuronidase activator Lactobacillus plants Lactic acid bacteria and Pediococcus lactic acid The content of lactic acid bacteria is not particularly limited unless the effects of the present invention are impaired, and may be appropriately selected depending on the intended purpose.
[0179] -use-
[0180] The above-mentioned glucuronidase activator has excellent glucuronidase activity, and therefore, can be used, for example, to increase the estrogen level in the body, improve the estrogen metabolism in the body, improve menopausal symptoms, or enhance the glucuronidase activity in the intestine. Therefore, a method for increasing the estrogen level in the body by administering the above-mentioned glucuronidase activator, a method for improving estrogen metabolism by administering the above-mentioned glucuronidase activator, a method for improving menopausal symptoms by administering the above-mentioned glucuronidase activator, and a method for enhancing the glucuronidase activity by administering the above-mentioned glucuronidase activator are also within the scope of the present invention.
[0181] Furthermore, the glucuronidase activator can be preferably used in the pharmaceutical composition, probiotic composition, edible composition, etc. described below, and can also be used as a reagent for research related to glucuronidase activity.
[0182] There are no particular limitations on the usage, dosage form, dosage to an individual, dosing interval, and subject of the glucuronidase activator, and the activator may be appropriately selected based on the age, condition, body weight, absorption of the active ingredient in the body, inactivity rate, excretion rate, presence or absence of a drug to be used in combination, and the type of the drug.
[0183] The usage of the glucuronidase activator is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include oral administration and parenteral administration.
[0184] Examples of the parenteral administration include transdermal, enteral, transmucosal, transvenous, transarterial, subcutaneous, and intramuscular administration.
[0185] Among them, oral administration is preferred.
[0186] The dosage form of the glucuronidase activator is not particularly limited and can be appropriately selected from known dosage forms according to usage, etc. The dosage form can be solid, semisolid, or liquid, and examples thereof include oral administration agents such as tablets, powders, capsules, soft capsules, granules, powders, oral liquids, elixirs, syrups, beverages, lozenges, and mouthwashes; and non-oral administration agents such as injections, infusions, sprays, inhalation dispersions, and suppositories.
[0187] The glucuronidase activator in the above dosage form can be produced by a known method.
[0188] As the subject of the above-mentioned glucuronidase activator, it is preferably applied to humans, but it can also be applied to animals other than humans (for example, mice, rats, hamsters, dogs, cats, cows, pigs, monkeys, horses, goats, birds, etc.) as long as their respective effects can be exerted.
[0189] (Pharmaceutical composition)
[0190] The pharmaceutical composition of the present invention contains a glucuronidase activator and a pharmaceutically acceptable carrier, and further contains other components as necessary.
[0191] It should be noted that the above-mentioned pharmaceutical composition is not limited to the administrative classification of pharmaceuticals, quasi-drugs, etc., and may be any of pharmaceuticals and quasi-drugs.
[0192] <Glucuronidase activator>
[0193] The glucuronidase activator contained in the pharmaceutical composition is as described in the above-mentioned item (glucuronidase activator).
[0194] The content of the glucuronidase activator in the pharmaceutical composition is not particularly limited and can be appropriately selected depending on the intended purpose.
[0195] <Pharmaceutically acceptable carrier>
[0196] The pharmaceutically acceptable carrier is not particularly limited and may be appropriately selected depending on the purpose, and examples thereof include additives, adjuvants, solvents, etc. These may be used alone or in combination of two or more.
[0197] The above-mentioned additives or auxiliary agents are not particularly limited and can be appropriately selected according to the purpose. Examples thereof include: excipients, bactericides, preservatives, adhesives, tackifiers, thickeners, binders, colorants, stabilizers, pH adjusters, buffers, isotonic agents, solvents, antioxidants, ultraviolet light inhibitors, crystallization inhibitors, defoaming agents, physical property improvers, preservatives, etc.
[0198] The excipients are not particularly limited and can be appropriately selected according to the purpose. Examples thereof include D-mannitol, white sugar (including purified white sugar), sodium bicarbonate, starch (for example, corn starch, potato starch, wheat starch, rice starch, partially pregelatinized starch, etc.), crystalline cellulose, light anhydrous silicic acid, calcium (anhydrous calcium hydrogen phosphate, precipitated calcium carbonate, calcium silicate, calcium stearate, etc.), and the like.
[0199] The solvent is not particularly limited and may be appropriately selected depending on the intended purpose. Examples thereof include water, physiological saline, and buffer solutions.
[0200] The content of the pharmaceutically acceptable carrier in the pharmaceutical composition is not particularly limited unless the effects of the present invention are impaired, and may be appropriately selected depending on the intended purpose.
[0201] The pharmaceutical composition can be used alone or in combination with a medicine having other components as active ingredients. In addition, the pharmaceutical composition can be used in a state of being combined with a medicine having other components as active ingredients.
[0202] There are no particular restrictions on the usage, dosage form, dosage amount for an individual, dosage interval, and individual subject of the pharmaceutical composition, and they can be appropriately selected according to the purpose. For example, they can be the same as the usage, dosage form, dosage amount for an individual, dosage interval, and individual subject of the glucuronidase activator. Among them, the usage of the pharmaceutical composition is preferably oral, and the dosage form of the pharmaceutical composition is preferably an oral administration agent. Therefore, the pharmaceutical composition can be preferably used as an oral composition.
[0203] In addition, the pharmaceutical composition in the above dosage form can be produced by a known method.
[0204] -use-
[0205] The pharmaceutical composition contains the glucuronidase activator having excellent glucuronidase activity and can therefore be preferably used, for example, to increase estrogen levels in the body, improve estrogen metabolism in the body, improve menopausal symptoms, or enhance glucuronidase activity in the intestine.
[0206] (Probiotic composition)
[0207] The probiotic composition of the present invention contains a glucuronidase activator and further contains other ingredients as necessary.
[0208] In this specification, "probiotics" refers to bacteria that exert beneficial effects in the intestines.
[0209] <Glucuronidase activator>
[0210] The glucuronidase activator contained in the probiotic composition is as described in the above-mentioned item (glucuronidase activator).
[0211] The content of the glucuronidase activator in the probiotic composition is not particularly limited and may be appropriately selected depending on the intended purpose. Alternatively, the probiotic composition may be the glucuronidase activator itself.
[0212] <Other ingredients>
[0213] As other components contained in the probiotic composition, the same components as those described in the item <Other components> of the above-mentioned (glucuronidase activator) can be used.
[0214] The content of the other components in the probiotic composition is not particularly limited unless the effects of the present invention are impaired, and may be appropriately selected depending on the intended purpose.
[0215] There are no particular restrictions on the usage, dosage form, dosage amount, dosage interval, and individual subject of the probiotic composition, and they can be appropriately selected according to the purpose. For example, they can be the same as the usage, dosage form, dosage amount, dosage interval, and individual subject of the glucuronidase activator. Among them, the usage of the probiotic composition is preferably oral, and the dosage form of the probiotic composition is preferably an oral administration agent. Therefore, the probiotic composition can be preferably used as an oral composition.
[0216] In addition, the probiotic composition in the above dosage form can be produced by a known method.
[0217] -use-
[0218] The probiotic composition contains the glucuronidase activator having excellent glucuronidase activity, and can be preferably used, for example, to increase estrogen levels in the body, improve estrogen metabolism in the body, improve menopausal symptoms, or enhance glucuronidase activity in the intestine.
[0219] (Edible composition)
[0220] The edible composition of the present invention contains a glucuronidase activator and an edible ingredient, and further contains other ingredients as necessary.
[0221] The edible composition refers to a substance that has little potential harm to human health and is taken orally in normal social life. Therefore, the edible composition widely includes foods such as general foods, health foods (functional beverage foods), health functional foods (specific health foods, nutritional functional foods, functional labeled foods), and patient foods that are taken orally. In addition, beverages are also included.
[0222] <Glucuronidase activator>
[0223] The glucuronidase activator contained in the edible composition is as described in the above-mentioned item (glucuronidase activator).
[0224] The content of the glucuronidase activator in the edible composition is not particularly limited and can be appropriately selected depending on the intended purpose.
[0225] <Edible Ingredients>
[0226] In the present specification, "edible ingredients" refer to edible ingredients other than those contained in the glucuronidase activator, which contain nutrients such as protein, lipid, carbohydrate, calcium, vitamins, carotene, etc. The edible ingredients are preferably edible ingredients for humans and animals other than humans.
[0227] The content of the edible ingredients in the edible composition is not particularly limited and can be appropriately selected depending on the type of the intended edible composition.
[0228] There is no particular limitation on the type of the edible composition, which can be appropriately selected according to the purpose, and examples thereof include: beverages such as lactic acid bacteria beverages, tea beverages, refreshing beverages, carbonated beverages, nutritional beverages, and fruit juice beverages; frozen desserts such as ice cream, sherbet, and shaved ice; noodles such as soba, udon, vermicelli, dumpling wrappers, shaomai wrappers, Chinese noodles, and instant noodles; desserts such as sugar, candy, chewing gum, chocolate, candy slices, snacks, biscuits, jelly, jam, cream, baked snacks, and bread; aquatic products or processed foods thereof such as crab, salmon, clams, tuna, sardines, shrimp, bonito, mackerel, whale, oyster, saury, squid, ark shell, scallop, abalone, sea urchin, salmon roe, and abalone; aquatic or livestock processed foods such as fish cakes, ham, and sausages; fermented milk, fermented soy milk, Dairy products such as processed milk, fermented milk, and yogurt; oils or oil-processed foods such as salad oil, tempura oil, margarine, mayonnaise, shortening, whipping cream, and seasoning sauces; seasonings such as sauces and dressings; steamed and cooked foods such as curry, stew, parent-child rice bowl, porridge, vegetable porridge, Chinese rice bowl, steak rice bowl, tempura rice bowl, eel rice bowl, diced meat and onion rice bowl, oden, mapo tofu, beef rice bowl, meat sauce, egg soup, omelette rice, dumplings, steamed buns, meat patties, and meatballs; dishes such as salads and pickles; various forms of foods for health, beauty, or nutritional supplements, etc.
[0229] The method for producing the edible composition is not particularly limited as long as the edible composition can contain the glucuronidase activator, and a known method can be appropriately selected according to the type of the edible composition.
[0230] The edible composition may be contained in a container. In addition, the container may have a label or instructions showing any effect selected from the following effects as the effect of the edible composition:
[0231] (a) Increase estrogen levels in the body; (b) Improve estrogen metabolism; and (c) Improve menopausal symptoms.
[0232] -use-
[0233] The edible composition contains the glucuronidase activator having excellent glucuronidase activity, and therefore, for example, can be used for increasing the estrogen level in the body, improving the estrogen metabolism in the body, improving menopausal symptoms, or enhancing the glucuronidase activity in the intestinal tract. In addition, it can also be preferably used as the probiotic composition.
[0234] (Composition for oral administration)
[0235] The oral composition of the present invention contains Lactobacillus breve with a preservation number of CECT 7480 ( Leviticus Actobacillus short )I-3141 strain, Lactobacillus plantarum with a deposit number of CECT 7481 ( Lactopl antibacterium plants ), and Pediococcus acidilactici with a preservation number of CECT 7483 ( Pediococcus acidilactici ), and further contain other ingredients as needed.
[0236] The above oral composition contains the lactobacillus breve with the accession number of CECT 7480 ( Levilactob acorn short )I-3141 strain, Lactobacillus plantarum with a deposit number of CECT 7481 ( Lactoplantib acillus plants ), and Pediococcus acidilactici with a preservation number of CECT 7483 ( Pediococcus dilactic acid ) is as described in the above-mentioned item (glucuronidase activator).
[0237] <Other ingredients>
[0238] As other components contained in the oral composition, the same components as those described in the item of <Other components> in the above-mentioned (glucuronidase activator) and the components described in the item of <Edible ingredients> in the above-mentioned (Edible composition) can be used.
[0239] The content of the other components in the oral composition is not particularly limited unless the effects of the present invention are impaired, and can be appropriately selected depending on the intended purpose.
[0240] (Composition containing microorganisms)
[0241] The composition containing microorganisms of the present invention contains Levilactobacillus short The I-3141 strain may further contain other components as required.
[0242] <I-3141 strain>
[0243] The I-3141 strain contained in the microorganism-containing composition is as described in the above-mentioned section (microorganism).
[0244] The content of the I-3141 strain in the microorganism-containing composition is not particularly limited and can be appropriately selected depending on the purpose. It should be noted that the microorganism-containing composition may be the I-3141 strain itself.
[0245] <Other ingredients>
[0246] The above-mentioned other components in the above-mentioned composition containing microorganisms are not particularly limited as long as they do not impair the effects of the present invention, and can be appropriately selected according to the purpose. For example, the same components as those described in the item of <Other components> of the above-mentioned (glucuronidase activator) can be used.
[0247] In addition, the above-mentioned microorganism-containing composition may contain other microorganisms.
[0248] As the other microorganisms, preferably Lactobacillus plants Lactic acid bacteria, and the above Pediococcus lactic acid 3 kinds of lactic acid bacteria of lactic acid bacteria, more preferably including lactic acid bacteria with a preservation number of CECT 7481 Lactobacillus plants , and CE CT 7483 Pediococcus lactic acid 3 types of lactic acid bacteria.
[0249] The method for producing the microorganism-containing composition is not particularly limited as long as the composition can contain the I-3141 strain, and a known method can be appropriately selected according to the purpose.
[0250] -use-
[0251] The above-mentioned composition containing microorganisms can also be preferably used for the above-mentioned probiotic composition, the above-mentioned glucuronidase activator, the above-mentioned pharmaceutical composition, the above-mentioned edible composition, and the like.
[0252] Example
[0253] Hereinafter, the present invention will be specifically described with reference to test examples and production examples, but the present invention is not limited to these test examples and production examples.
[0254] (Test Example 1)
[0255] Lactic acid bacteria having β-glucuronidase activity capable of deconjugating the glucuronic acid conjugate of estrogen were screened by the following method.
[0256] MRS liquid medium (BD Difco TMLactobacillus MRS broth, manufactured by Becton Dickinson Company), will contain Levilactobacillus short 375 lactic acid bacteria strains including NBRC 107147 strain (obtained from NBRC), which was a standard strain, were pre-cultured (static culture) at 37°C for 24 hours.
[0257] Next, the cells were cultured in MRS liquid medium (BD Difco) supplemented with 5-bromo-4-chloro-3-indolyl-β-D-glucuronide cyclohexylammonium (X-Gluc) (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.) at a final concentration of 200 μg / mL. TM Each lactic acid bacterium pre-cultured in the above-mentioned MRS liquid medium was inoculated into Lactobacillus MRS broth (Becton Dickinson) to a final concentration of 0.1% (v / v), and static culture was performed at 37°C for 72 hours.
[0258] After the culture was completed, the color of the culture solution was checked, and lactic acid bacteria whose culture solution showed a blue-green color from blue due to the presence of a blue pigment (5,5'-dibromo-4,4'-dichloroindigo) generated by hydrolysis of X-Gluc were selected as lactic acid bacteria having GUS activity.
[0259] The selected lactic acid bacteria is strain I-3141 (accession number: CECT 7480). The bacteriological characteristics of strain I-3141 are as described in the above-mentioned item (microorganisms). Levilactobacillus short s of lactic acid bacteria.
[0260] In addition, as Levilactobacillus short The NBRC 107147 strain, which is a benchmark strain, also has GUS activity.
[0261] (Test Example 2)
[0262] Using the I-3141 strain selected in Test Example 1 and the NBRC 107147 strain, which was a reference strain, GUS activity and substrate specificity were confirmed by the following method.
[0263] <Preparation of bacterial cell disruption solution>
[0264] MRS liquid medium (BD Difco TMLactobacillus MRS broth, manufactured by Becton Dickinson Co., Ltd.), and the I-3141 strain or the NBRC 107147 strain was pre-cultured (static culture) at 37°C for 24 hours.
[0265] Then, in MRS liquid medium (BD Difco TM Each lactic acid bacterium pre-cultured in the above-mentioned MRS liquid medium was inoculated into Lactobacillus MRS broth (manufactured by Becton Dickinson) at a final concentration of 0.1% (v / v), and cultured at 37°C for 48 hours.
[0266] After the cultivation is completed, the culture solution is centrifuged to remove the culture supernatant to obtain the cultured lactic acid bacteria. The lactic acid bacteria are added with a GUS buffer (100 mM sodium phosphate buffer, pH 6.0, added with 2.5 mM ethylenediaminetetraacetic acid) in an amount equal to the culture supernatant removed, and the cells are washed and centrifuged to remove the supernatant. The lactic acid bacteria are washed for the second time in the same manner to obtain the lactic acid bacteria.
[0267] The obtained lactic acid bacteria were suspended by adding the GUS buffer in an amount 24 times (v / w) of the amount of the bacteria, and then, glass beads in an amount 20 times (w / w) of the amount of the bacteria were added, and the cells were disrupted using Multi-Beads Shocker (registered trademark) (manufactured by Yasui Instruments Co., Ltd.). Then, the disrupted product was centrifuged to obtain a supernatant (lactic acid bacteria disrupted liquid).
[0268] <Evaluation of GUS activity>
[0269] 4-nitrophenyl β-D-glucuronide (pNGP) (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.), estrone 3-(β-D-glucuronide) (E1-3G) (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.), or estradiol 3-(β-D-glucuronide) (E2-3G) (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.) as a substrate was added to the obtained cell disruption solution of each lactic acid bacteria (the final protein concentration was adjusted to 0.25 mg / mL with the above-mentioned GUS buffer) at a final concentration of 1.0 mM, and the reaction was carried out at 37°C, and the concentration of the product generated by the GUS activity at the start of the reaction (0 minute) and 15 minutes, 30 minutes, 45 minutes, and 60 minutes after the start of the reaction was measured to evaluate its activity. In addition, the above-mentioned GUS buffer was used instead of the cell disruption solution, and only the above-mentioned substrate was used to perform the same test as a negative control.
[0270] Specifically, when 4-nitrophenyl β-D-glucuronide (pNGP) was used as the substrate, the absorbance at 405 nm was measured every 15 minutes after the reaction started using a microplate reader. The concentration of pNP generated by GUS activity was calculated based on the absorbance at 405 nm of 4-nitrophenol (pNP) (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.) of various concentrations measured separately.
[0271] In addition, when estrone 3-(β-D-glucuronide) (E1-3G) or estradiol 3-(β-D-glucuronide) (E2-3G) is used as a substrate, a 25 mass % trichloroacetic acid solution (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.) is added every 15 minutes after the reaction starts to stop the reaction. After the reaction stops, the supernatant is recovered by centrifugation, and the concentration of E1-3G or E2-3G in the supernatant is quantified by high performance liquid chromatography (HPLC) under the following conditions. Based on the decrease in the concentration of E1-3G or E2-3G, the concentration of estrone (E1) or estradiol (E2) generated by GUS activity is calculated.
[0272] The results are shown in Table 4 and Figure 2~4 .
[0273] [HPLC analysis conditions]
[0274] ·Device: Prominence (manufactured by Shimadzu Corporation)
[0275] Column: YMC-Pack ODS-A (particle size 5 μm, pore size 12 nm, inner diameter 4.6 mm×length 250 mm) (manufactured by YMC Corporation)
[0276] Column temperature: 40℃
[0277] Mobile phase: 0.1 vol% formic acid acetonitrile solution: 0.1 vol% formic acid aqueous solution = 45:55 (v / v)
[0278] Injection volume: 10μL
[0279] Flow rate: 0.7 mL / min
[0280] Detector: Photodiode array detector SPD-M20A (manufactured by Shimadzu Corporation)
[0281] [Table 4]
[0282]
[0283] According to Table 4 and Figure 2~Figure 4 The results showed that the I-3141 strain had higher product concentrations for all three substrates than the NBRC 107147 strain, which was the reference strain, and had excellent glucuronidase activity.
[0284] (Test Example 3)
[0285] Using the I-3141 strain selected in Test Example 1, the effect on estrogen in the blood was tested by the following method.
[0286] Nine-week-old female germ-free mice (strain name: C57BL / 6N Jcl) (CLEA Japan) were divided into two groups: a solvent control group and an I-3141-administered group.
[0287] Mice in the vehicle control group (n=7) were orally administered with normal saline three times a week for 2 weeks.
[0288] The mice in the I-3141 administration group (n=7) were orally administered with I-3141 strain 3 times a week for 2 weeks. At this time, I-3141 strain was suspended in physiological saline at 1×10 9 The dosage was CFU / unit / time.
[0289] Blood was collected 2 weeks after administration (when mice in each group were 11 weeks old) and serum was separated. The concentration of estradiol (E2) in serum was determined by liquid chromatography tandem mass spectrometry (LC-MS / MS) based on the method described in Japanese Patent No. 6041125 (LC-MS / MS analysis was entrusted to Asuka Pharmac eutical Medical). The specific determination method is described below.
[0290] In Test Example 3, the concentration of estradiol (E2) in serum was measured only for individuals determined to be in estrus by the following method.
[0291] Vaginal smears were collected at the same time as the above blood collection. The vaginal smears were spread on a slide, dried, and Giemsa-stained to prepare sections of the vaginal smear images. The estradiol concentration of individuals judged to be in estrus based on the vaginal smear images (solvent control group: 3, I-3141-administered group: 5) was measured by the following method, and the average value of each group was calculated. The difference between the two groups was analyzed using the Student's t-test, and the case where the p value (probability value) was p < 0.05 was considered statistically significant. The results are shown in Table 6 below.
[0292] <Preparation of samples for calibration curve>
[0293] As samples for calibration curve, 50 μL of methanol solutions of estradiol E2 (manufactured by FUJIFILM Wako Pure Chemical Co., Ltd.) (0.01 pg / 50 μL, 0.05 pg / 50 μL, 0.1 pg / 50 μL, 1 pg / 50 μL, 10 pg / 50 μL, and 100 pg / 50 μL) were added to test tubes, and the volume was adjusted to 1 mL with purified water.
[0294] <Preparation of serum samples for measurement>
[0295] <<Step 1: Dissolution of estradiol (E2)>>
[0296] The internal standard (E2- 13 C4) 10pg / 50μL, further add 4mL of methyl tert-butyl ether, and shake for 5 minutes. Then, the aqueous phase is frozen and separated, and after the solvent of the oil phase is distilled off, the residue is dissolved in 0.5mL of methanol and 1mL of purified water is added. It is added to Oasis (registered trademark) MAX Cartridge (manufactured by Waters) which has been adjusted in advance with 3mL of methanol and then with 3mL of purified water. Then, after the above-mentioned cartridge is washed with 1mL of 1 volume % acetic acid, 1mL of 30 volume % acetonitrile, 1mL of 1M sodium hydroxide, 3mL of methanol, 1mL of 1 volume % acetic acid and 1mL of pyridine / 60 volume % methanol (1:100 (volume ratio)), estradiol (E2) is eluted with 1mL of pyridine / 90 volume % methanol (1:100 (volume ratio)), and the eluate is distilled off with a centrifugal evaporator.
[0297] <<Step 2: Preparation of E2-3-tetrafluoropyridyl ether>>
[0298] To the residue obtained in step 1, 0.05 mL of pentafluoropyridine, 0.1 mL of acetonitrile and 0.02 mL of triethylamine were added, and the mixture was thoroughly shaken and allowed to stand at room temperature for 20 minutes. After the reaction, the reaction reagents were distilled off under reduced pressure.
[0299] <<Step 3: Elution of E2-3-tetrafluoropyridyl ether>>
[0300] To the residue obtained in step 2, 0.14 mL of a solution of 1 mg of 2-hydrazino-1-methylpyridine dissolved in 1% by volume trifluoroacetic acid-acetonitrile (1:1,400 (volume ratio)) was added, and the mixture was allowed to stand at room temperature for 1 hour. The method for producing 2-hydrazino-1-methylpyridine is described in Japanese Patent Application Laid-Open No. 2010-36810.
[0301] After the reaction, the solvent was distilled off under reduced pressure. After dissolving the residue with 0.5 mL of methanol, 0.5 mL of purified water was added. It was added to an Oasis (registered trademark) WCX Cartridge that had been adjusted in advance with 3 mL of methanol and then with 3 mL of purified water. Then, for the above-mentioned Cartridge, after washing the Cartridge column with 1 mL of 0.1 M potassium dihydrogen phosphate, 2 mL of purified water and 1 mL of 40% by volume acetonitrile, E2-3-tetrafluoropyridyl ether was eluted with 1 mL of methanol, and the solvent was distilled off under reduced pressure.
[0302] <<Step 4: Preparation of E2-3-tetrafluoropyridyl ether-17-fusaric acid derivative>>
[0303] The residue containing E2-3-tetrafluoropyridyl ether obtained in step 3 was dried under reduced pressure for more than 30 minutes, and then, a derivatization reagent (40 mg of fusaric acid, 40 mg of 2-methyl-6-nitrobenzoic anhydride, 20 mg of 4-dimethylaminopyridine / 1 mL of acetonitrile) 0.05 mL and 0.01 mL of triethylamine were added and left at room temperature for 30 minutes. After the reaction, 0.5 mL of hexane / acetic acid (50:1 (volume ratio)) was added to the reaction solution and the mixture was thoroughly shaken and mixed. The mixture was added to an InertSep (registered trademark) SI Cartridge which had been adjusted in advance with 3 mL of ethyl acetate and then with 3 mL of hexane. Then, after washing the above-mentioned cartridge with 1 mL of hexane and 2 mL of ethyl acetate / hexane (15:85 (volume ratio)), E2-3-tetrafluoropyridyl ether-17-fusaric acid derivative (E2-TfpyFU) was eluted with ethyl acetate / hexane (45:55 (volume ratio)), and the eluate was distilled off under reduced pressure. The residue was dissolved with 0.1 mL of 80 volume % acetonitrile to prepare an E2-TfpyFU solution.
[0304] <Measurement of estradiol (E2) concentration>
[0305] 0.02 mL of the E2-TfpyFU solution obtained in step 4 was injected into LC-MS / MS and measured under the measurement conditions shown in Table 5 below. The ESI mass spectrum when E2-TfpyFU was measured by the mass analyzer detected an intact protonated ion at m / z 583. In addition, MS / MS measurement was performed using m / z 583 as the precursor ion, and the result showed that m / z 308 was the product ion with the highest specificity. Therefore, these ions were used for selective reaction monitoring (SRM) measurement and quantification.
[0306] [Table 5]
[0307] LC-MS / MS conditions for E2-TfpyFU
[0308]
[0309] [Table 6]
[0310]
[0311] *: p<0.05
[0312] From the results in Table 6, it was confirmed that the concentration of estradiol in the blood was significantly increased by administration of the I-3141 strain.
[0313] (Production Example 1)
[0314] A food containing the I-3141 strain selected in Test Example 1 was produced by the following method.
[0315] Based on the following formula, the following three kinds of mixed powders of lactic acid bacteria (obtained from AB-BIOTICS SA) were mixed with dry starch and calcium stearate as excipients to obtain a powder composition for capsule filling. Then, a capsule filling machine (LIQFIL-superJCF, Qualicaps) was used to fill an average of 280 mg of the above-mentioned powder composition per capsule in a hard capsule (QUALI-V (registered trademark)-N, Qualicaps) to manufacture a food.
[0316] <Formulation of powder composition>
[0317] Mixed powder of three lactic acid bacteria (dry powder of I-3141 strain (0.5×10 9 CFU / capsule), Lactobacillus plants CECT 7481(0.25×10 9 CFU / capsule), and Pediococcus lactic acid CECT 7483(0.25×10 9 CFU / capsule): 75mg
[0318] Dry starch (dried potato starch, manufactured by Matsutani Chemical Industry Co., Ltd.): 199 mg
[0319] Calcium stearate (calcium stearate (vegetable), manufactured by Taihei Chemical Industry Co., Ltd.): 6 mg
[0320] (Test Example 4)
[0321] Using the food produced in Production Example 1 (hereinafter sometimes referred to as "test food"), the effect of the food on estrogen in the blood was tested by the following method.
[0322] <Manufacturing of control food>
[0323] In Production Example 1, a control food was produced in the same manner as in Production Example 1, except that the three types of lactic acid bacteria were not added and the total amount of the three types of lactic acid bacteria (75 mg) was changed to 75 mg of dry starch (dried potato starch, manufactured by Matsutani Chemical Industries, Ltd.).
[0324] <Test method>
[0325] 111 menopausal women were divided into two groups, which were set as the control food intake group (57, average age 49.95 ± 0.32 years old) and the test food intake group (54, average age 50.35 ± 0.40 years old). The control food intake group took 1 capsule of the above control food once a day after breakfast, and took it orally for 12 consecutive weeks. The test food intake group took 1 capsule of the above test food once a day, and took it orally for 12 consecutive weeks. Blood was collected at the beginning of the test (before the initial intake) and after the 12-week intake, and serum was separated.
[0326] <<Measurement of estradiol (E2) concentration>>
[0327] By the same method as in Test Example 3, the concentration of estradiol (E2) in serum was measured.
[0328] <<Measurement of estrone (E1) concentration>>
[0329] The concentration of estrone (E1) in serum was measured by liquid chromatography tandem mass spectrometry (LC-MS / MS) based on the method described in Japanese Patent No. 6041125 (LC-MS / MS analysis was commissioned to Asuka Pharmaceutical Medical). The specific measurement method is described below.
[0330] <Preparation of samples for calibration curve>
[0331] As samples for calibration curve, 50 μL of methanol solutions of estrone (E1) (manufactured by FUJIFILM WakoPure Chemical Co., Ltd.) (0.05 pg / 50 μL, 0.1 pg / 50 μL, 0.25 pg / 50 μL, 1 pg / 50 μL, 10 pg / 50 μL, and 100 pg / 50 μL) were added to test tubes, and the volume was adjusted to 1 mL with purified water.
[0332] <Preparation of serum samples for measurement>
[0333] <<Step 1: Dissolution of estrone (E1)>>
[0334] Internal standard (E1- 13 C4) 10pg / 50μL, further add 4mL of methyl tert-butyl ether, and shake for 5 minutes. Then, the aqueous phase is frozen and separated, and after the solvent of the oil phase is distilled off, the residue is dissolved in 0.5mL of methanol and 1mL of purified water is added. It is added to Oasis (registered trademark) MAX Cartridge (manufactured by Waters) which has been adjusted in advance with 3mL of methanol and then with 3mL of purified water. Then, the above-mentioned cartridge is washed with 1mL of 1 volume % acetic acid, 1mL of 30 volume % acetonitrile, 1mL of 1M sodium hydroxide, 3mL of methanol, 1mL of 1 volume % acetic acid and 1mL of pyridine / 60 volume % methanol (1:100 (volume ratio)), and estrone (E1) is eluted with 1mL of pyridine / 90 volume % methanol (1:100 (volume ratio)), and the eluate is distilled off with a centrifugal evaporator.
[0335] As described in Test Example 3, in this method, when estrone (E1) is eluted, estradiol (E2) is also eluted simultaneously.
[0336] <<Step 2: Preparation of E1-3-tetrafluoropyridyl ether>>
[0337] To the residue obtained in step 1, 0.05 mL of pentafluoropyridine, 0.1 mL of acetonitrile and 0.02 mL of triethylamine were added, and the mixture was thoroughly shaken and allowed to stand at room temperature for 20 minutes. After the reaction, the reaction reagents were distilled off under reduced pressure.
[0338] <<Step 3: Elution of E2-3-tetrafluoropyridyl ether>>
[0339] To the residue obtained in step 2, add 0.14 mL of a solution of 1 mg of 2-hydrazino-1-methylpyridine dissolved in 1% by volume trifluoroacetic acid-acetonitrile (1:1,400 (volume ratio)), and leave at room temperature for 1 hour. After the reaction, the solvent is distilled off under reduced pressure. After dissolving the residue with 0.5 mL of methanol, 0.5 mL of purified water is added. Add it to an Oasis (registered trademark) WCX Cartridge that has been adjusted in advance with 3 mL of methanol and then with 3 mL of purified water. Then, for the above-mentioned Cartridge, after washing the Cartridge column with 1 mL of 0.1M potassium dihydrogen phosphate, 2 mL of purified water and 1 mL of 40% by volume acetonitrile, E2-3-tetrafluoropyridyl ether is eluted with 1 mL of methanol, and the solvent is distilled off under reduced pressure.
[0340] Next, the cartridge was washed with 2 mL of acetonitrile, 0.5 mL of purified water, and 1 mL of formic acid / 65% by volume methanol (1:50 (volume ratio)), and then E1-3-tetrafluoropyridyl ether-17-(1'-methylpyridine) was added with 1 mL of formic acid / methanol (1:50 (volume ratio)). -2')-hydrazone derivative (E1-TfpyHMP) was eluted. The solvent was distilled off from the eluate under reduced pressure. The residue was dissolved in 0.1 mL of 70 vol% acetonitrile to prepare an E1-TfpyHMP solution.
[0341] <Measurement of estrone (E1) concentration>
[0342] 0.02 mL of the E1-TfpyHMP solution obtained in step 3 was injected into LC-MS / MS and measured under the measurement conditions shown in Table 7 below. The ESI mass spectrum when E1-TfpyHMP was measured by the mass analyzer detected a complete protonated ion at m / z 525. In addition, MS / MS measurement was performed using m / z 525 as a precursor ion, and the result was that m / z 308 was the most specific product ion, so these ions were used for selective reaction monitoring (SRM) measurement and quantification.
[0343] [Table 7]
[0344] LC-MS / MS conditions for determination of E1-TfpyHMP
[0345]
[0346] <<Statistical Analysis>>
[0347] For the measured serum estrone (E1) concentration and estradiol (E2) concentration, covariance analysis (ANCOVA) was performed, and correction was made using the serum E1 concentration at the start of the test (before the first intake) or the serum E2 concentration at the start of the test (before the first intake) and age. For the difference between the two groups, the case where the p value (probability value) was p < 0.05 was considered statistically significant. The results are shown in Table 8 below.
[0348] [Table 8]
[0349]
[0350] *: p<0.05
[0351] From the results of Table 8, it was confirmed that the blood estrogen (E1 and E2) concentrations significantly increased in the test food ingestion group containing three types of lactic acid bacteria.
[0352] As an aspect of the present invention, for example, the following aspects etc. can be mentioned.
[0353] <1> A glucuronidase activator, comprising Lactobacillus breve with a preservation number of CECT 7480 ( Levilactobacillus short )I-3141 strain as the active ingredient.
[0354] <2> The glucuronidase activator according to <1> above, wherein the above-mentioned Lactobacillus breve ( Levilactobacillus short )I-3141 strain is in the form of dried or crushed material.
[0355] <3> The glucuronidase activator according to any one of <1> to <2> above, further comprising a member selected from the group consisting of Lactobacillus plantarum ( Lactobacillus plants ) and lactic acid bacteria belonging to Pediococcus acidilactici ( Pediococcus lactic acid ) at least any one of the lactic acid bacteria.
[0356] <4> The glucuronidase activator according to <3> above, wherein the above-mentioned Lactobacillus plantarum ( Lactobacillus plants ) is Lactobacillus plantarum with the accession number of CECT 7481 ( Lactobacillus plants )F-2096 strain.
[0357] <5> The glucuronidase activator according to any one of <3> to <4> above, wherein the above-mentioned bacterium belongs to Pediococcus acidilactici ( Pediococcus lactic acid ) is a lactic acid bacterium with the accession number of CECT 7483 ( Pediococcus lactic acid )F-1033 strain.
[0358] <6> The glucuronidase activator according to any one of <1> to <5> above, which is used for increasing estrogen levels in the body.
[0359] <7> The glucuronidase activator according to any one of <1> to <5> above, which is used for improving estrogen metabolism.
[0360] <8> The glucuronidase activator according to any one of <1> to <5> above, which is used for improving menopausal symptoms.
[0361] <9> A method for enhancing the activity of glucuronidase, the method comprising:
[0362] The subject was administered with Lactobacillus breve (CECT 7480). Levilactobacillus short )I-3141 strain and enhanced glucuronidase activity.
[0363] <10> The method for enhancing the glucuronidase activity according to <9> above, wherein the above-mentioned Lactobacillus breve ( Levilactobacillus short )I-3141 strain is in the form of dried or crushed material.
[0364] <11> The method for enhancing the glucuronidase activity according to any one of <9> to <10>, further comprising using a bacterium selected from the group consisting of Lactobacillus plantarum ( Lactobacillus plants ) and at least any one of lactic acid bacteria belonging to Pediococcus acidilactici.
[0365] <12> The method for enhancing the activity of glucuronidase according to <11>, wherein the above-mentioned Lactobacillus plantarum ( Lactobacillus plants ) is Lactobacillus plantarum with the accession number of CECT 7481 ( Lactobacillus plants )F-2096 strain.
[0366] <13> The method for enhancing the activity of glucuronidase according to any one of <11> to <12>, wherein the bacterial strain belonging to Pediococcus acidilactici ( Pediococcus lactic acid ) is the lactic acid bacteria of accession number: CECT7483 ( Pediococcus lactic acid )F-1033 strain.
[0367] <14> A pharmaceutical composition comprising the glucuronidase activator according to any one of <1> to <8> above and a pharmaceutically acceptable carrier.
[0368] <15> The pharmaceutical composition according to <14> above, which is a composition for oral administration.
[0369] <16> An edible composition comprising the glucuronidase activator according to any one of <1> to <8> above and an edible ingredient.
[0370] <17> The edible composition according to <16> above, which is a probiotic composition.
[0371] <18> The edible composition according to any one of <16> to <17>, contained in a container having a label or instructions indicating at least one of the following effects as an effect of the edible composition:
[0372] (a) Increase estrogen levels in the body,
[0373] (b) Improve estrogen metabolism, and
[0374] (c) Improve menopausal symptoms.
[0375] <19> The edible composition according to <18>, wherein the edible composition is a health functional food.
[0376] <20> An oral composition containing Lactobacillus breve with a preservation number of CECT 7480 ( Levilactobacillus short )I-3141 strain, Lactobacillus plantarum with a deposit number of CECT 7481 ( Lactobacillus plants ), and Pediococcus acidilactici with a preservation number of CECT 7483 ( Pediococcus lactic acid ).
[0377] <21> A composition containing microorganisms, which contains Lactobacillus breve with a preservation number of CECT 7480 ( Levilactobacillus short )I-3141 strain.
[0378] <22> The composition containing microorganisms according to <21> above, further comprising a microorganism selected from the group consisting of Lactobacillus plantarum ( Lactobacillus plants ) and lactic acid bacteria belonging to Pediococcus acidilactici ( Pediococcus lactic acid ) at least any one of the lactic acid bacteria.
[0379] <23> The composition containing microorganisms according to <22>, wherein the above-mentioned Lactobacillus plantarum ( Lactobacillus plants ) is Lactobacillus plantarum with the accession number of CECT 7481 ( Lactobacillus plants )F-2096 strain.
[0380] <24> The composition containing microorganisms according to any one of <22> to <23> above, wherein the above-mentioned Pediococcus acidilactici ( Pediococcus lactic acid ) is a lactic acid bacterium with a preservation number of CECT 7483 ( Pediococcus lactic acid )F-1033 strain.
[0381] <25> Lactobacillus breve with the accession number CECT 7480 ( Levilactobacillus short ) Use of I-3141 strain for enhancing glucuronidase activity.
[0382] <26> Lactobacillus breve with the accession number CECT 7480 ( Levilactobacillus short ) Use of I-3141 strain for increasing estrogen levels.
[0383] <27> Lactobacillus breve with the accession number CECT 7480 ( Levilactobacillus short ) Use of I-3141 strain for improving estrogen metabolism.
[0384] <28> A glucuronidase activator for increasing estrogen levels as described in any one of <1> to <8> above, a pharmaceutical composition as described in any one of <14> to <15> above, an edible composition as described in any one of <16> to <19> above, an oral composition as described in <20> above, or a composition containing a microorganism as described in any one of <21> to <24> above.
[0385] <29> A glucuronidase activator according to any one of <1> to <8>, a pharmaceutical composition according to any one of <14> to <15>, an edible composition according to any one of <16> to <19>, an oral composition according to <20>, or a composition containing a microorganism according to any one of <21> to <24>, for improving estrogen metabolism.
[0386] <30> A glucuronidase activator according to any one of <1> to <8>, a pharmaceutical composition according to any one of <14> to <15>, an edible composition according to any one of <16> to <19>, an oral composition according to <20>, or a composition containing a microorganism according to any one of <21> to <24>, for improving menopausal symptoms.
[0387] <31> A microorganism, which is deposited as CECT 7480 Levilactobacillus short strain I-3141, which has glucuronidase activity.
[0388] <32> A method for enhancing the activity of glucuronidase, the method comprising:
[0389] The glucuronidase activator described in any one of <1> to <8>, the pharmaceutical composition described in any one of <14> to <15>, the edible composition described in any one of <16> to <19>, the oral composition described in <20>, or the composition containing a microorganism described in any one of <21> to <24> is orally administered to a subject.
[0390] <33> A method for increasing estrogen levels in the body, the method comprising:
[0391] The glucuronidase activator described in any one of <1> to <8>, the pharmaceutical composition described in any one of <14> to <15>, the edible composition described in any one of <16> to <19>, the oral composition described in <20>, or the composition containing a microorganism described in any one of <21> to <24> is orally administered to a subject.
[0392] <34> A method for improving estrogen metabolism, the method comprising:
[0393] The glucuronidase activator described in any one of <1> to <8>, the pharmaceutical composition described in any one of <14> to <15>, the edible composition described in any one of <16> to <19>, the oral composition described in <20>, or the composition containing a microorganism described in any one of <21> to <24> is orally administered to a subject.
[0394] <35> A method for improving menopausal symptoms, the method comprising:
[0395] The glucuronidase activator described in any one of <1> to <8>, the pharmaceutical composition described in any one of <14> to <15>, the edible composition described in any one of <16> to <19>, the oral composition described in <20>, or the composition containing a microorganism described in any one of <21> to <24> is orally administered to a subject.
[0396] The present international application claims the benefit of priority based on Japanese Patent Application No. 2022-042917 filed on March 17, 2022, the entire contents of which are incorporated herein by reference.
[0397] Accession number
[0398] CECT 7480
[0399] CECT 7481
[0400] CECT 7483.
Claims
1. A glucuronidase activator, comprising Lactobacillus breve with a preservation number of CECT 7480 ( Levilactobacillusbrevis )I-3141 strain as the active ingredient.
2. The glucuronidase activator according to claim 1, further comprising a member selected from the group consisting of Lactobacillus plantarum ( Lactoplantibacillus plantarum ) and lactic acid bacteria belonging to Pediococcus acidilactici ( Pediococcusacidilactici ) at least any one of the lactic acid bacteria.
3. The glucuronidase activator according to claim 2, in, The plant bacteria belongs to Lactoplantibacillus plantarum ) is the lactic acid bacteria of accession number: Lactobacillus plantarum ( Lactoplantibacillus plantarum )F-2096 strain.
4. The glucuronidase activator according to claim 2 or 3, in, The Pediococcusacidilactici ) is a lactic acid bacterium with the accession number of CECT 7483 ( Pediococcusacidilactici )F-1033 strain.
5. The glucuronidase activator according to any one of claims 1 to 4, which is used for increasing the estrogen level in the body. 6 . The glucuronidase activator according to claim 1 , which is used for improving estrogen metabolism.
7. The glucuronidase activator according to any one of claims 1 to 4, which is used for improving menopausal symptoms.
8. A method for enhancing the activity of glucuronidase, the method comprising: include: The subject was administered with Lactobacillus breve (CECT 7480). Levilactobacillusbrevis )I-3141 strain and enhanced glucuronidase activity. 9 . A pharmaceutical composition comprising the glucuronidase activator according to claim 1 and a pharmaceutically acceptable carrier. 10 . The pharmaceutical composition according to claim 9 , which is a composition for oral administration. 11 . An edible composition comprising the glucuronidase activator according to claim 1 and an edible ingredient.
12. The edible composition according to claim 11, which is a probiotic composition.
13. The edible composition according to claim 11 or 12, contained in a container having a label or instructions indicating at least any one of the following effects as the effect of the edible composition: (a) Increase estrogen levels in the body, (b) Improve estrogen metabolism, and (c) Improve menopausal symptoms.
14. An oral composition comprising Lactobacillus breve with a preservation number of CECT 7480 ( Levilactobacillusbrevis )I-3141 strain, Lactobacillus plantarum with a deposit number of CECT 7481 ( Lac toplantibacillus plantarum ), and Pediococcus acidilactici with a preservation number of CECT 7483 ( Pedioco ccusacidilactici ).
15. A method for increasing estrogen levels, the method include: The glucuronidase activator according to any one of claims 1 to 4, the pharmaceutical composition according to claim 9 or 10, the edible composition according to any one of claims 11 to 13, or the oral composition according to claim 14 is orally administered to a subject.
16. A method for improving estrogen metabolism, the method include: The glucuronidase activator according to any one of claims 1 to 4, the pharmaceutical composition according to claim 9 or 10, the edible composition according to any one of claims 11 to 13, or the oral composition according to claim 14 is orally administered to a subject.
17. A method for improving menopausal symptoms, the method include: The glucuronidase activator according to any one of claims 1 to 4, the pharmaceutical composition according to claim 9 or 10, the edible composition according to any one of claims 11 to 13, or the oral composition according to claim 14 is orally administered to a subject.
